COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.
Laureen Yi-Ting WangGavin Yeow Ping NgPublished in: European heart journal. Case reports (2020)
Current efficacy and safety evidence of lopinavir-ritonavir as a treatment in COVID-19 patients is limited. Although uncommonly reported, those with underlying cardiovascular disease are at increased risk of bradyarrhythmia-related adverse effects of lopinavir-ritonavir. When initiating investigational therapies, especially in patients with cardiovascular conditions, adequate counselling and close monitoring are required.
Keyphrases
- cardiovascular disease
- sars cov
- coronavirus disease
- antiretroviral therapy
- randomized controlled trial
- clinical trial
- hiv infected
- hepatitis c virus
- combination therapy
- cardiovascular risk factors
- replacement therapy
- men who have sex with men
- human immunodeficiency virus
- smoking cessation
- phase ii
- electronic health record